Yuki Noguchi
Yuki Noguchi is a correspondent on the Science Desk based out of NPR's headquarters in Washington, D.C. She started covering consumer health in the midst of the pandemic, reporting on mental health, vaccination, telehealth, and racial inequities in healthcare.
Noguchi started her career as a reporter, then an editor, for The Washington Post, primarily covering business and technology. Noguchi joined NPR as a business correspondent in 2008, just before the financial crisis and Great Recession. She has covered a wide range of issues, from the workplace to the earthquake and tsunami in her parents' native Japan in 2011. Her coverage of the impact of opioids on workers and their families won a 2019 Gracie Award as well as First Place and Best In Show in the radio category from the National Headliner Awards. Her work on medical debt, in partnership with Kaiser Health News, won a 2023 Gerald Loeb award and an award from the National Institutes of Health Care Management.
Noguchi grew up in St. Louis, likes to cook, has a degree in history from Yale and is raising two boys and two rescue dogs outside Washington DC.
-
From state and local food-safety response to the federal health agencies that fund that work, a record-breaking year for cyclosporiasis cases runs up against the Trump administration's cuts last year. -
The FDA says lettuce distributed by Taylor Fresh Foods and Taylor Farms de Mexico is still linked to the multistate outbreak of cyclosporiasis. But the source may be difficult to definitively trace. -
The FDA could approve the first blood test that can detect multiple cancers, around the end of the year, setting the stage for it to become widely available. -
Recent studies suggest the weight loss and diabetes drugs may prevent cancer and slow its progression. While weight loss is known to curb cancer risks, GLP-1s may act on other brain and metabolic pathways to prevent cancer. -
Pancreatic cancer is notoriously lethal. But new treatments mean that may be changing, and people with the disease now have more reason to hope than ever before. -
It's a very treatable form of cancer if caught early, yet younger adults rarely get screened. Patient advocates want more people to talk to their doctors about risk factors and number two. -
Unlike many cancers, colorectal cancer has become more lethal for people at younger ages. Doctors are sleuthing out why. -
A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again. Research hasn't yet shown the health impacts of cycling on and off the drugs. -
Big food companies are starting to market to people on the powerful new obesity meds with labels that say "GLP-1 Friendly." Nutritionists help us decode that message. -
The anti-parasitic drug became a household name during the COVID-19 pandemic, and it is now being embraced as an alternative treatment for cancer. It is as politically polarizing as ever.
